Immix Biopharma Inc
NASDAQ:IMMX

Watchlist Manager
Immix Biopharma Inc Logo
Immix Biopharma Inc
NASDAQ:IMMX
Watchlist
Price: 2.89 USD 9.06% Market Closed
Market Cap: 80.6m USD

EV/EBIT
Enterprise Value to EBIT

-3
Current
-1.9
Median
4.9
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3
=
Enterprise Value
64.6m USD
/
EBIT
-21.8m USD
EBIT Growth EV/EBIT to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average EV/EBIT: 20.6
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -345 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.4
2-Years Forward
EV/EBIT
-2.3
3-Years Forward
EV/EBIT
N/A